24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Licensing
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
14:12
OpenAI, Nvidia, and the bubble debate: Lessons from 30 years of tech surges
13:42
The Elephant appoints Oded Harniv as Chief Information Officer
13:31
CTech's Book Review: The art of building genuine human relationships
12:06
The return of the pay raise: Why companies are betting on money over perks
More stories
Buzz
Most popular
Daily
Weekly
1
After $5B valuation, cyber unicorn Island doubles down on Israel with new R&D center
2
The 9-to-9 workday is back and it’s spreading beyond Silicon Valley
3
He built a billion-dollar tech empire. Now he’s bankrupt and still believes it’s temporary.
4
Ilya Sutskever breaks silence on OpenAI departure: “I had a big new vision”
5
Cyber unicorn Axonius cuts more than 10% of staff amid restructuring
More news
Licensing
4 stories about Licensing
Israeli roads off-limits to Tesla Cybertruck due to licensing issues
18.07.24
|
Tomer Hadar
Ministry of Transportation holds back approval over bulletproof concerns
“Licensing practices are tilting the market in favor of certain providers against others”
07.05.22
|
James Spiro
Francisco Mingorance, Executive General at CISPE, explains how cloud monopolies are affecting licensing agreements online
Israel to Set Up Fast Track for Licensing Fintech Projects
19.08.19
|
Meir Orbach
According to the Israeli Ministry of Finance, there are currently 2,000 different entities awaiting licensing, many of which are fintech and blockchain companies that need to make only slight adjustments to comply with current regulations
Teva Reaches Confidential Patent Settlement with Neos
27.12.18
|
CTech
The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026